[Bronchodilators--effective also in negative broncholysis test. Decreased dyspnea decreased in any case]

MMW Fortschr Med. 2002 Apr 11;144(15):34-6, 38.
[Article in German]

Abstract

According to GOLD (Global Initiative for Chronic Obstructive Lung Disease), bronchodilator drugs are indicated for all degrees of severity of COPD. In stage 1, short-acting substances are administered as required; in stage 2, permanent treatment with short- or long-acting bronchodilators is applied. Patients who fail to respond to broncholysis testing can also benefit from such treatment over the long term. Combination treatment with beta 2 sympathomimetics and anticholinergic drugs makes good sense, since additive effects can develop. Since COPD patients often have CAD in addition, consideration must be given to cardiac side effects--in particular in the case of theophylline. The sole life-prolonging treatment for COPD continues to be the long-term administration of oxygen; the only measure capable of stopping progressive deterioration of lung function is cessation of smoking.

Publication types

  • English Abstract

MeSH terms

  • Administration, Inhalation
  • Airway Resistance / drug effects*
  • Asthma / diagnosis
  • Asthma / drug therapy
  • Bronchodilator Agents / adverse effects
  • Bronchodilator Agents / therapeutic use*
  • Diagnosis, Differential
  • Drug Therapy, Combination
  • Dyspnea / diagnosis
  • Dyspnea / drug therapy*
  • Humans
  • Practice Guidelines as Topic
  • Pulmonary Disease, Chronic Obstructive / diagnosis
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Treatment Outcome

Substances

  • Bronchodilator Agents